Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PBGENE-DMD

Gene editing · developed by Precision BioSciences

Phase 1/2 Most advanced trial

DTIL Developer

1 Registered trials

What is PBGENE-DMD?

PBGENE-DMD is a single-dose investigational agent studied in Duchenne muscular dystrophy in patients with mutations amenable to PBGENE-DMD.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene editing
Therapy area: Musculoskeletal
Developer: Precision BioSciences, Inc. (DTIL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07429240	Phase 1/2	Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD	Recruiting	DTIL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

More from Precision BioSciences

PBGENE-HBV Phase 1

Sources

ClinicalTrials.gov NCT07429240

Updated Oct 11, 2026. Something wrong or missing? Report it on the DTIL page.

Follow DTIL, the company behind PBGENE-DMD

See DTIL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DTIL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z